| |
|
SHS Newsletter – To open this newsletter in your browser, please click here.
|
| |
|
|
|
| |
April 2021
|
 |
|
|
|
| |
| |
|
Dear Sir or Madam,
|
| |
Since the last newsletter, a lot has happened again: We can report on one new mid-market investment and two successful exits.
In a strong growth phase, we sold the homecare specialist medigroba to Löwenstein Group. And with the exit of CryLaS, we handed over a profitable, fast-growing high-tech company in the field of laser technology to a strategic investor.
We recently provided growth capital to the medium-sized specialist for drug delivery systems Develco Pharma. We talk to CEO Dr. Martin Renner about the medical benefits of special formulation systems and the economic prospects in this market segment.
We introduce you to our Senior Advisor Heinz Jacqui, who has been well-connected in the medtech world for decades and knows what challenges SMEs face in medical technology.
Hardly any other topic is currently being highlighted in the financial world as much as investing according to ESG criteria. This is a good thing, but of course nothing entirely new. At SHS, we have been investing according to ESG principles for almost 30 years and have also anchored them institutionally. My colleague André Zimmermann explains in more detail how we do this.
If you connect with us on LinkedIn, you can always stay up to date on everything important in healthcare and medical technology and find out what is happening at SHS.
Best regards from Tübingen
|
| |
|
| |
|
Hubertus Leonhardt
|
|
|
.jpeg)
|
| |
| |
|
Topics
|
| |
| • |
The Portfolio Interview: Dr. Martin Renner, CEO Develco Pharma
|
| |
|
|
| • |
ESG Investing at SHS: Part 2
|
| |
|
|
| • |
3 Questions for: Heinz Jacqui, Senior Advisor at SHS
|
| |
|
|
|
| • |
Exit after strong growth: Homecare specialist medigroba GmbH sold to Löwenstein Group
|
| |
|
|
| • |
Successful exit: SHS sells stake in CryLaS, a specialist in laser technology for the healthcare, biotech and semiconductor industries
|
| |
|
|
| • |
Functional spinal implants from Blue Ocean Spine give patients hope
|
| |
|
|
| • |
New CEO at active ingredient specialist AMW to drive international expansion
|
| |
|
|
| • |
c-LEcta receives EXCiPACT certification: accolade for high quality standard
|
| |
|
|
| • |
Danish specialist clinic for epilepsy relies on AI-based diagnostic system from Neuro Event Labs
|
| |
|
|
| • |
Novel GFRNMR test from numares guarantees more precise testing of kidney function
|
| |
|
|
| • |
Completed study shows clear benefits of SIS high-pressure balloon catheters for calcified and severely calcified heart vessels and in-stent restenosis
|
| |
|
|
| • |
On course for growth despite pandemic: Tyromotion, leading manufacturer of technology-based rehabilitation equipment
|
| |
|
|
|
| • |
Worth listening to: SHS partner Dr. André Zimmermann in the EIT Health podcast interview
|
| |
|
|
| • |
"Digitalisation in medical technology": The medtech column by Dr. André Zimmermann
|
| |
|
|
|
|
|
|
|
| • |
Jobs at Portfolio Companies
|
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
The Portfolio Interview: Dr. Martin Renner, CEO Develco Pharma |
|
|
| |
| |
|
|
In an interview, CEO Dr. Martin Renner explains why the portfolio company Develco Pharma is so successful with its drug delivery systems and why the medium-sized company chose SHS as a growth investor.
|
|
|
|
|
|
| |
| |
|
|
| |
ESG Investing at SHS: Part 2 |
|
|
| |
| |
Do good and get a return! Read here how socially responsible investment (ESG) is anchored at SHS and what it has to do with the fight against Corona.
|
|
|
|
|
|
|
|
| |
| |
|
|
| |
3 Questions for: Heinz Jacqui, Senior Advisor at SHS |
|
|
| |
| |
|
|
Heinz Jacqui has worked for many years in top management in the medtech industry. He knows the challenges facing internationally operating medtech SMEs.
|
|
|
|
|
|
| |
| |
|
|
|
|
|
| |
Exit after strong growth: Homecare specialist medigroba GmbH sold to Löwenstein Group |
|
|
| |
| |
|
|
SHS sells homecare company medigroba to Löwenstein Group. Another exit to a strategic partner.
|
|
|
|
|
|
| |
| |
|
|
| |
Successful exit: SHS sells stake in CryLaS, a specialist in laser technology for the healthcare, biotech and semiconductor industries |
|
|
| |
| |
With the sale of the laser specialist CryLaS, SHS announces another successful exit.
|
|
|
|
|
|
|
|
| |
| |
|
|
| |
Functional spinal implants from Blue Ocean Spine give patients hope |
|
|
| |
| |
|
|
Novel, customisable spinal implants from Blue Ocean Spine give patients with chronic back pain reason for hope.
|
|
|
|
|
|
| |
| |
|
|
| |
New CEO at active ingredient specialist AMW to drive international expansion |
|
|
| |
| |
New CEO at drug delivery systems specialist AMW to dynamically drive product and company development.
|
|
|
|
|
|
|
|
| |
| |
|
|
| |
c-LEcta receives EXCiPACT certification: accolade for high quality standard |
|
|
| |
| |
|
|
Successful enzyme manufacturer c-LEcta receives the globally recognised EXCiPACT quality certification. This means more safety and transparency for the entire pharmaceutical supply chain with reduced audit costs for industrial customers.
|
|
|
|
|
|
| |
| |
|
|
| |
Danish specialist clinic for epilepsy relies on AI-based diagnostic system from Neuro Event Labs |
|
|
| |
| |
The Finnish SHS portfolio company Neuro Event Labs Oy announces an extensive cooperation with Filadelfia Epilepsy Hospital in Dianalund.
|
|
|
|
|
|
|
|
| |
| |
|
|
| |
Novel GFRNMR test from numares guarantees more precise testing of kidney function |
|
|
| |
| |
|
|
Diagnostics specialist numares AG develops multi-marker algorithm for more accurate test of kidney function.
|
|
|
|
|
|
| |
| |
|
|
| |
Completed study shows clear benefits of SIS high-pressure balloon catheters for calcified and severely calcified heart vessels and in-stent restenosis |
|
|
| |
| |
With 30 atm pressure into the calcified coronary wall. High-pressure balloon catheter from SIS convinces in study.
|
|
|
|
|
|
|
|
| |
| |
|
|
| |
On course for growth despite pandemic: Tyromotion, leading manufacturer of technology-based rehabilitation equipment |
|
|
| |
| |
|
|
Tyromotion defies the pandemic and grows with high-tech rehab equipment - also in Australia.
|
|
|
|
|
|
| |
| |
|
|
|
|
|
| |
Worth listening to: SHS partner Dr. André Zimmermann in the EIT Health podcast interview |
|
|
| |
| |
|
|
Is the MDR a killer for innovations in the medtech industry? Dr. André Zimmermann addresses this question in the EIT Health Podcast.
|
|
|
|
|
|
| |
| |
|
|
| |
"Digitalisation in medical technology": The medtech column by Dr. André Zimmermann |
|
|
| |
| |
In his Medtech column, André Zimmermann writes about "Digitisation in medical technology: megatrend as megachance".
|
|
|
|
|
|
|
|
| |
| |
|
|
|
|
| |
| |
.jpeg "Praktikanten Sundermann Wolf") |
| |
| Justin Sundermann (l) and Sascha Wolf (r) |
|
|
|
A new and an old face at SHS: Justin Sundermann returns and Sascha Wolf starts at SHS.
|
|
|
|
|
|
| |
| |
|
|
|
|
|
|
|
| |
| |
(Senior) Investment Manager (m/f/d) – full-time or part-time
Read more »
|
|
| |
Assistant Marketing & Communication (m/f/d) – Full-time (40h) or part-time (30h)
Read more »
|
|
| |
Private Equity & Venture Capital Internship
Read more »
|
|
| |
Entrepreneur (m/f/d) wanted: Management Buy-in/Buy-out (MBI/MBO)
Read more »
|
|
|
| |
| |
|
|
| |
Jobs at Portfolio Companies |
|
|
| |
| |
Head of Sales & Marketing (m/f/d)
Read more »
|
|
| |
Further vacancies at our portfolio companies
Read more »
|
|
|
| |
| |
|
|
|
|
|
| |
| |
ZAK Zollern-Alb-Kurier, 23 April 2021: „Zeichen stehen auf Wachstum: SHS verkauft Balinger Homecare-Unternehmen Medigroba" (Signs point to growth: SHS sells Balingen-based homecare company Medigroba) |
|
| |
The Zollern-Alb-Kurier reports on the sale of homecare specialist medigroba to the Löwenstein Group. |
|
| |
Read more » |
|
|
| |
| |
Frankfurter Allgemeine Zeitung, 15 April 2021: „Die jungen Wilden“ (The Young Savages) |
|
| |
The FAZ reports on digital start-ups, including SHS portfolio company Selfapy, which has been on the market since 2016 with its online therapy for depression, among other things. |
|
| |
Read more » |
|
|
| |
| |
Plattform Life Sciences, 01-2021: „Sentiment – Stimmungslage unter Investoren und Finanzierungsberatern 2021“ (Sentiment - Sentiment among investors and financing advisors 2021) |
|
| |
Awareness of healthcare has increased significantly," says SHS partner Manfred Ulmer-Weber in an interview with several investors from the life science environment. |
|
| |
Read more » |
|
|
| |
| |
ZETRA International – Newsletter January 2021: "Interview Sascha Alilovic" |
|
| |
SHS Managing Partner Sascha Alilovic explains in an interview with ZETRA International AG why a partnership with a private equity sector fund such as SHS can create additional value for medtech SMEs and how he assesses the medtech & M&A market in Switzerland. |
|
| |
Read more » |
|
|
| |
| |
unquote, 14 January 2021: SHS sells stake in Single UseSupport |
|
| |
Unquote reports the sale of Austrian life science supplier Single Use Support GmbH to Pall Corporation. |
|
| |
Read more » |
|
|
| |
| |
|
|
| |
|
|
| |
Investment focus
|
|
| |
|
|
| |
| Sector: |
|
life sciences (medical technology, diagnostics, applied technologies, digital health, industrial biotechnology/pharmaceutical industry; no drug development) |
| Geographical Focus: |
|
Germany, Austria, Switzerland, Scandinavia, Benelux |
| Reasons for investment: |
|
growth capital, strengthening equity, MBO/MBI, change of shareholders/succession, M&A financing, spin-off |
| Company situation: |
|
growth/expansion, succession/company sale, internationalization; operating profit may be negative for growth, or for technology-related reasons |
| Transaction value and investment size: |
|
transaction value: up to € 100m; investment amount:
€ 2-30m, with a co-investor from the SHS-network up to € 60m |
| Investment types: |
|
majorities or minorities, equity & financial instruments similar to equity |
|
|
| |
|
|
|
|
|
| |
|
|
| |
The newsletter is published by SHS Gesellschaft für Beteiligungsmanagement mbH
|
|
| |
|
|
| |
Bismarckstrasse 12 | 72072 Tuebingen | Germany | www.shs-capital.eu
Tel +49 7071 9169-0 | Fax +49 7071 9169-190
|
|
| |
|
|
| |
|
Editorial team: SHS Gesellschaft für Beteiligungsmanagement mbH
Design and technical realisation: UNIBRAND GmbH
|
|
To unsubscribe the newsletter, please click here. If you like us to delete your data, please send an email with the subject „data deletion“ to tuebingen@shs-capital.eu.
|
|
|
| |
|
|
|
|
| |
|
.jpeg "AZ_Innohealth.jpg")
.jpeg "200526_Heinz.Jacqui_1.jpg")
.jpeg "medigroba_Flyerbild.jpg")
.jpeg "CRL2.jpg")
.jpeg "BOS.jpg")
.jpeg "AMW.jpg")
.jpeg "nelli_pro.jpg")
.jpeg "NUM.2.jpg")
.jpeg "SIS.jpg")
.jpeg "TYR.jpg")
.jpeg "Speaking.like_.an_.investor-1024x576.jpg")
.jpeg "Zimmermann_Andre_medtech_zwo_Finanzkolumne-1024x576.jpg")